The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10568 malaria professionals are enjoying the free benefits of MalariaWorld today


NOT Open Access | Novel insights into Plasmodium vivax therapeutic failure: CYP2D6 activity and time of exposure to malaria modulate the risk of recurrence

March 9, 2020 - 14:21 -- NOT Open Access
Silvino ACR, Kano FS, Costa MA, Fontes CJF, Soares IS, Brito CFA, Carvalho LH, Sousa TN
Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02056-19

Plasmodium vivax relapse is one of the major causes of sustained global malaria transmission. Primaquine (PQ) is the only commercial drug available to prevent relapses, and its efficacy is dependent on metabolic activation by cytochrome P450 2D6 (CYP2D6). Impaired CYP2D6 function, caused by allelic polymorphisms, leads to the therapeutic failure of PQ as a radical cure for P. vivax malaria.

K13-propeller gene polymorphisms of Plasmodium falciparum and the therapeutic effect of artesunate among migrant workers returning to Guangxi, China (2014–2017)

October 22, 2019 - 16:36 -- Open Access
Jun Li, Yunliang Shi, Jian Qin, et al.
Malaria Journal 2019 18:349, 16 October 2019

The resistance of Plasmodium falciparum to artemisinin has been identified in Asia and some parts of Africa. The drug resistance of P. falciparum will be an obstacle to the successful elimination of malaria by 2025. Whole-genome sequencing of the artemisinin-resistant parasite line revealed mutations on the k13 gene associated with drug resistance in P. falciparum. To understand the artemisinin resistance of the imported P. falciparum cases from Africa, the mutations in the k13 gene in parasites from imported malaria cases in Guangxi Province were detected and the treatment efficiency of artesunate monotherapy was observed.

Medical Condition: 
Medical Treatment: 
Subscribe to RSS - therapeutic